Assume this: Positive ongoing results show real prospect for...

Assume this:
Positive ongoing results show real prospect for partner and company that commercialisation is the likely outcome for the partnership.

Delivered phase 1 of the work program with Collaborator 1 in April and agreed phase 2 validation program. Work with Collaborator 2 (is ongoing with progressive results having been exchanged). Work with Collaborator 3 announced July will get underway through Q3 2019.

This is in line with one of my previous posts in which I argued that ongoing results would render a testing regime unnecessary to extend to its full anticipated period if those progressive results would not be positive and encouraging.
Management gives shareholders a little hint here, IMO.
We were told to expect news from phase 2 of collaborator 1 by August/ Sept.
Now we are told that second part of the year will see results being shared.

The confidentiality clauses tighten around the collaborative work of both partners, as I see it, and management is not even prepared, or allowed, to share anything ongoing from that partnership at the anticipated date.
Why would that be?
Given the global race for silicon based or enriched anodes, this is little surprising and holds actual promise of great progress within the program to shareholders.
The next news we might hear in regards of that collaboration might contain financial details under a proper deal.

Anteo has filed its patent application in 18 countries either directly or via the European Patent Organization where the Company will be targeting initially 5 key member countries. The applications continue to progress through the various jurisdictions

Within the group of partnerships, AnteoCoat might be part of the European EV rollout early/ mid next decade.
Does tight lipped confidentiality really surprise in this context?

All IMO.​